In vivo treatment with GDF-9 stimulates primordial and primary follicle progression and theca cell marker CYP17 in ovaries of immature rats

Citation
Ua. Vitt et al., In vivo treatment with GDF-9 stimulates primordial and primary follicle progression and theca cell marker CYP17 in ovaries of immature rats, ENDOCRINOL, 141(10), 2000, pp. 3814-3820
Citations number
55
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
ENDOCRINOLOGY
ISSN journal
00137227 → ACNP
Volume
141
Issue
10
Year of publication
2000
Pages
3814 - 3820
Database
ISI
SICI code
0013-7227(200010)141:10<3814:IVTWGS>2.0.ZU;2-9
Abstract
Growth differentiation factor (GDF)-9 is a cystine knot-containing hormone of the transforming growth factor-beta superfamily produced by the oocyte. In GDF-9 null mice, follicle development is arrested at the primary stage a nd GDF-9 treatment in vitro enhances preantral follicle growth. Immature fe male rats were treated with recombinant GDF-9 for 7 or 10 days. At 10 days, treatment with GDF-9 augmented ovarian weights, concomitant with an increa se in the number of primary and small preantral follicles by 30 and 60%, re spectively. Furthermore, the number of primordial follicles was decreased b y 29%, but the number of large preantral follicles was not affected. In con trast, treatment with FSH increased the number of small and large preantral follicles by 36 and 177% but did not influence the number of primary and p rimordial follicles. Immunoblot analysis showed an increase of CYP17, a the ca cell marker, in the ovarian homogenate after treatment with GDF-9 but no t FSH. The present results indicate that in vivo treatment with GDF-9 enhan ces the progression of primordial and primacy follicles into small preantra l follicles. Thus, GDF-9 treatment could provide an alternative approach to stimulate early follicle development in addition to the widely used FSH th at acts mainly on the development of more advanced follicles.